Chemokines and alcoholic hepatitis: are chemokines good therapeutic targets?

Current paradigms about chemokines as therapeutic targets.

After the recognition of chemotactic cytokines as mediators of inflammation about a decade ago, specific chemokine antagonists are now approaching first clinical trials for non-renal indications [1]. In the field of nephrology, the potential of targeting the chemokine system has also gained much interest. In general, cytokines orchestrate cell–cell communication in order either to maintain tiss...

Chemokines and chemokine receptors as therapeutic targets in lupus nephritis.

Recruitment of leukocytes is a characteristic feature of tissue injury in systemic lupus erythematosus, including lupus nephritis. Locally secreted chemokines and their receptors are important mediators of leukocyte recruitment to the specific sites of immune complex injury, and contribute to renal inflammatory disease in the initiation and progression phase. Therefore, chemokines and chemokine...

Cytokines and chemokines as therapeutic targets for ischemic kidney injury

Cytokines and chemokines induce the migration, activation, proliferation, and/or differentiation of inflammatory cells and resident cells, and participate in the pathogenesis of some autoimmune diseases. Some of these molecules are effective therapeutic targets. Anti-tumor necrosis factor (TNF)-α and anti-interleukin (IL)-6 therapies are effective in patients with rheumatoid arthritis, and have...

Chemokines: established and novel targets in atherosclerosis

In their role as small chemotactic cytokines, chemokines are crucial mediators and regulators of leukocyte trafficking during immune surveillance and inflammation. Their involvement in the development and progression of inflammatory diseases has been subject of intense investigation. Concordantly, the chemokine system has been explored in search for therapeutic targets to prevent or treat infla...

Chemokines.